Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy (2022) Fasching P, Huang M, Haiderali A, Xue W, Pan W, Karantza V, Yang F, et al. Conference contribution Incorporating progesterone receptor expression into the PREDICT breast prognostic model (2022) Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, et al. Journal article Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry (2022) Muller V, Hein A, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, et al. Journal article, Original article Treatment-relevant biomarkers in gynecologic oncology (2022) Ditsch N, Fasching P Journal article Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial (2022) Trapp EK, Fasching P, Fehm T, Schneeweiss A, Mueller V, Harbeck N, Lorenz R, et al. Journal article Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting (2022) Erber R, Angeloni M, Stöhr R, Lux MP, Ulbrich-Gebauer D, Pelz E, Bankfalvi A, et al. Journal article Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer (2022) Fasching P, Liu D, Scully S, Ingle JN, Lyra PC, Rack B, Hein A, et al. Journal article Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study (2022) Dixon-Suen SC, Lewis SJ, Martin RM, English DR, Boyle T, Giles GG, Michailidou K, et al. Journal article Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer (2022) Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, Hu P, et al. Journal article Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288, (Annals of Oncology (2019) 30(1279-1288) (S0923753419312785)) (2022) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article, Erratum